Physician profile
Robert Fulop
NPI 1861461345
$6,886.66
in general payments reported to CMS, 2019-2025
31 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $828 · 2021: $990 · 2022: $1,267 · 2023: $1,219 · 2024: $1,234 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,632.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $968.06 | 2021-2025 | |
| Lilly USA, LLC | $865.65 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $752.08 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $590.97 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $556.11 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $514.25 | 2020-2025 | |
| Amgen INC. | $412.09 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.13 | 2022-2025 | Jardiance |
| Pfizer INC. | $356.11 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $240.09 | 2019-2025 | Lagevrio, Capvaxive |
| Medtronic, INC. | $174.88 | 2021 | |
| Allergan, INC. | $124.97 | 2020 | |
| Sanofi-Aventis U.S. LLC | $123.00 | 2019-2022 | |
| Esperion Therapeutics, INC. | $116.23 | 2020-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $105.15 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.13 | 2022-2023 | |
| Amarin Pharma, INC. | $83.42 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $69.81 | 2020-2022 | |
| Abbott Laboratories | $44.26 | 2021 | |
| Eisai INC. | $43.27 | 2020-2021 | |
| Astellas Pharma US INC | $43.02 | 2024 | Veozah |
| Insightec,INC | $29.38 | 2025 | Exablate |
| Axsome Therapeutics, INC. | $22.21 | 2025 | Symbravo |
| Inspire Medical Systems, INC. | $21.17 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $20.59 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $19.66 | 2021 | |
| Horizon Therapeutics Plc | $16.50 | 2022 | |
| Exact Sciences Corporation | $16.46 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $14.57 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.44 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fulop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.